Molecular design of peptide therapeutics via N-terminal modification
Authors:
- 25 April 2024
- book chapter
- Published by Elsevier
- Vol. 698, 195-219
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of conceptCell Metabolism, 2022
- Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese miceMolecular Metabolism, 2022
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of conceptMolecular Metabolism, 2018
- Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal ImpairmentClinical Pharmacokinetics, 2017
- Oligomerization of a Glucagon-like Peptide 1 Analog: Bridging Experiment and SimulationsBiophysical Journal, 2015
- Peptide therapeutics: current status and future directionsDrug Discovery Today, 2015
- Rapid Flow‐Based Peptide SynthesisChemBioChem, 2014
- Trifluoroacetaldehyde: A useful industrial bulk material for the synthesis of trifluoromethylated amino compoundsJournal of Fluorine Chemistry, 2010
- Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIPDiabetologia, 2002
- Statistical determination of the average values of the extinction coefficients of tryptophan and tyrosine in native proteinsAnalytical Biochemistry, 1992